Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204

Cancer

Volumn 119, Issue 8, 2013, Pages 1521-1527

  Landry, Jerome C ^a   Feng, Yang ^b   Cohen, Steven J ^c   Staley III, Charles A ^a   Whittington, Richard ^d   Sigurdson, Elin Ruth ^c   Nimeiri, Halla ^e   Verma, Udit ^f   Prabhu, Roshan S ^a   Benson, Al Bowen ^e  

^a EMORY UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

chemoradiation; colorectal cancer; combined modality therapy; neoadjuvant therapy; radiation therapy; rectal cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ABDOMINAL ABSCESS; ABDOMINAL PAIN; ABSCESS DRAINAGE; ADD ON THERAPY; ADULT; ADVANCED CANCER; AGED; ANASTOMOSIS DEHISCENCE; ANASTOMOSIS LEAKAGE; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; BRAIN HEMORRHAGE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; DEEP VEIN THROMBOSIS; DEHYDRATION; DESQUAMATION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPOTENSION; ILEUS; INTENSITY MODULATED RADIATION THERAPY; INTESTINE OBSTRUCTION; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PREOPERATIVE CARE; PRIORITY JOURNAL; PROCTITIS; PULMONARY ASPIRATION; RADIATION DOSE; RECTAL PAIN; RECTUM ABDOMINOPERINEAL RESECTION; RECTUM CANCER; RECTUM CARCINOMA; RECTUM DISEASE; RECTUM FISTULA; RECTUM LOW ANTERIOR RESECTION; RECTUM SURGERY; RECTUM TOTAL MESORECTAL EXCISION; RECURRENCE FREE SURVIVAL; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; WEIGHT REDUCTION; WOUND HEALING IMPAIRMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; POSTOPERATIVE PERIOD; RADIOTHERAPY DOSAGE; RECTAL NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84876030092     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27890     Document Type: Article

References (23)

1. Siegel R, Ward E, Brawley O, Jemal A,. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61: 212-236.
2. Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med. 1985; 312: 1465-1472.
3. Greene FL, American Joint Committee on Cancer, American Cancer Society. AJCC Cancer Staging Manual. 6th edition. New York: Springer-Verlag, 2002.
4. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004; 351: 1731-1740.
5. Roh MS, Yothers GA, O'Connell MJ, et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04 [Abstract]. J Clin Oncol. 2011; 29 (suppl): abstract 3503.
6. Hess S, Blackstock AW,. In vitro and in vivo evidence of its radiation sensitizing activity: Preclinical observation relevant to ongoing clinical trials [Abstract]. Proceedings of the 91st Annual Meeting of the American Association of Cancer Research (AACR) 2000; 335: Abstract.
7. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E,. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther. 2002; 1: 227-235.
8. Gerard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405- Prodige 2. J Clin Oncol. 2010; 28: 1638-1644.
9. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-2342.
10. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999; 59: 3374-3378.
11. Lee CG, Heijn M, di Tomaso E, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 2000; 60: 5565-5570.
12. Czito BG, Bendell JC, Willett CG, et al. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: phase I trial results. Int J Radiat Oncol Biol Phys. 2007; 68: 472-478.
13. Willett CG, Duda DG, di Tomaso E, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol. 2009; 27: 3020-3026.
14. Crane CH, Eng C, Feig BW, et al. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2010; 76: 824-830.
15. Landry JC, Catalano P, Cohen SJ, et al. Phase II study of preoperative radiation with concurrent capecitabine, oxaliplatin and bevacizumab followed by surgery and postoperative 5-FU, leucovorin, oxaliplatin (FOLFOX) and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204. Int J Radiat Oncol Biol Phys. 2009; 75 (suppl): S27-S28.
16. Aschele C, Pinto C, Cordio S, et al. Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: Pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial. J Clin Oncol. 2009; 27 (18 suppl): abstract CRA4008.
17. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol. 2005; 91: 173-180.
18. Varadhachary GR, Wolff RA, Crane CH,. Preoperative gemcitabine (gem) and bevacizumab (bev)-based chemoradiation for resectable pancreatic adenocarcinoma. J Clin Oncol. 2008; 26 (May 20 suppl): 4630.
19. Bege T, Lelong B, Viret F, et al. Bevacizumab-related surgical site complication despite primary tumor resection in colorectal cancer patients. Ann Surg Oncol. 2009; 16: 856-860.
20. Dipetrillo T, Pricolo V, Lagares-Garcia J, et al. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2012; 82: 124-129.
21. García-Aguilar J, Hernandez de Anda E, Sirivongs P, Lee S-H, Madoff R, Rothenberger D,. A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum. 2003; 46: 298-304.
22. Pucciarelli S, Toppan P, Friso ML, et al. Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome. Dis Colon Rectum. 2004; 47: 1798-1807.
23. Park IJ, You YN, Agarwal A, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol. 2012; 30: 1770-1776.